Plain-English translation of NCT03275194 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment called hyperthermic intraperitoneal chemotherapy (HIPEC) — a procedure where heated chemotherapy drugs (cisplatin and doxorubicin) are placed directly into the abdomen during surgery — to see if it can reduce the chance that advanced ovarian cancer will return. The study involves women who have already had initial chemotherapy and are undergoing surgery to remove as much cancer as possible. Researchers want to know if adding this heated chemotherapy treatment during surgery improves outcomes compared to surgery alone.
Ovarian cancer is often found at an advanced stage and tends to come back in about 70% of patients within two years, even after standard surgery and chemotherapy. This trial is testing whether applying heated chemotherapy directly to the area where cancer cells are most likely to spread could help prevent recurrence and improve survival.
You likely qualify if…
You likely don't qualify if…
If you qualify and agree to participate, you will first receive 3 or 4 cycles of standard chemotherapy. Then you'll have interval surgery to remove as much cancer as possible. After surgery, you will be randomly assigned to one of two groups: either you receive the heated chemotherapy treatment (HIPEC) directly into your abdomen, or you receive surgery alone. You'll be monitored throughout with blood tests, imaging scans, and follow-up visits to track how well the treatment is working and any side effects you may experience.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Mexico